TP53 and neoplasm: Furthermore, we found that sub-chronic doxorubicin treatments (200 μg/kg) significantly induced the numbers of CSCs (CD44v6+/CD133+), by threefold (4.9% vs. 1.7% of total tumor cells, p<0.001) in TP53 tumors, as compared to SW48-generated tumors in mice (Figure 7A).